PIM Kinases Are a Potential Prognostic Biomarker and Therapeutic Target in Neuroblastoma

Abstract excerpt

Abstract The majority of high-risk neuroblastoma patients are refractory to, or relapse on, current treatment regimens, resulting in 5-year survival rates of less than 50%. This emphasizes the urgent need to identify novel therapeutic targets. Here, we report that high PIM kinase expression is correlated with poor overall survival. Treatment of neuroblastoma cell lines with the pan-PIM inhibitors AZD1208 or...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Mechanisms and Therapy
• Share to Neuroblastoma Research and Treatments
• Share to Neurofibromatosis and Schwannoma Cases